Innotech Precision Medicine, Inc.
Boston, MA
- UEI
- E4LRXHW2EKS5
- CAGE
- 8LKY4
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 11 Parkside Dr, Jamaica Plain, MA 02130, USA
- Website
- innotechprecisionmed.com
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $0 |
| FY2024 | $243,500 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Ncezid topic 031 - phase i development of sherlock assay | CDC Pittsburgh | $243,500 |
Grant awards
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| Emory University | U54EB027690 | $50,000 |
Similar vendors
About the company
Innotech Precision Medicine, Inc. is a woman-owned small business and minority-owned corporation registered in SAM.gov, specializing in developing advanced diagnostic technologies with a focus on point-of-care molecular detection systems. The company appears to concentrate on creating innovative diagnostic platforms for early disease detection, particularly in cancer and viral screening, with a strong emphasis on developing portable, rapid, and non-invasive testing solutions that leverage cutting-edge technologies like microfluidics, AI, and electrochemical detection methods.
For federal contract awards, Innotech Precision Medicine, Inc. has secured a $243,500 firm fixed-price definitive contract with the Centers for Disease Control and Prevention (CDC) for the Phase I development of the SHERLOCK assay under the NCEZID TOPIC 031 program. The contract was a total small business set-aside with performance located in Atlanta, Georgia, and an ultimate completion date of March 9, 2025. The contract represents a targeted, specialized scientific development project focused on advancing diagnostic assay technologies for potential public health applications.
Regarding federal grant awards, Innotech has received multiple significant project grants from agencies like the National Institute of Dental and Craniofacial Research (NIDCR), National Science Foundation (NSF), and the Office of the Director. These grants support the development of innovative diagnostic technologies, including a saliva-based point-of-care diagnostic test for oropharyngeal squamous cell carcinoma (RECOGNIZE-OPSCC), a microfluidic device for multi-omics cancer diagnosis, and a multiplexed sensor platform for COVID-19 screening. The grants range from $305,000 to $1,414,853 and involve collaborative partnerships with institutions like Massachusetts Institute of Technology (MIT) and Emory University. The projects consistently focus on developing rapid, non-invasive diagnostic technologies that can improve early disease detection, reduce healthcare costs, and potentially save lives by enabling timely intervention.
Quick answers
Is Innotech Precision Medicine, Inc. registered in SAM.gov?
Yes. Innotech Precision Medicine, Inc.'s SAM.gov registration is active through July 13, 2027.
How much has Innotech Precision Medicine, Inc. received in federal contracts?
Federal contracts obligated $243,500 to Innotech Precision Medicine, Inc. in fiscal years 2023 through 2027.
What is Innotech Precision Medicine, Inc.'s most recent federal award?
Innotech Precision Medicine, Inc.'s most recent federal grant award is Point of care detection of HPV and P16 in saliva (R44DE033312), from National Institute of Dental and Craniofacial Research (NIH), on August 8, 2025.
On GovTribe
See Innotech Precision Medicine, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors